Companies Announcements Office
Australian Securities Exchange Limited
10th Floor, 20 Bridge Street
SYDNEY NSW 2000
MEC Resources Ltd (ASX MMR) Notice of General Meeting under Section 249F and
MMR Rights Issue
Dear Sir/Madam,
Correspondence has been received on behalf of MMR raising a number of
objections to the form of the notice issued to MMR for a General Meeting under
Section 249F of the Corporations Act 2001.
Whilst those objections are being considered and legal advice is received the
Notice of General Meeting under section 249F is being withdrawn and is intended
to be re-submitted once these objections have been considered.
MMR Rights Issue
MMR has recently announced that Grandbridge Limited (Grandbridge) did not
take up any entitlements under the MMR Rights issue. Grandbridge had and still
has concerns in relation to a range of matters in relation to the rights issue and
MMR’s disclosure and has referred these for review to ASIC. Until those matters
are addressed Grandbridge would not invest in MMR’s Rights issue.
MMR is an ASX listed pooled development fund (PDF). The PDF program operates
under the Pooled Development Funds Act 1992 (Cth) (PDF Act) and is
administered by the Venture Capital Committee of Innovation Australia
(Innovation Australia).
A PDF may only invest 30% of its shareholder funds into any one investee unless the
board of Innovation Australia consents to a PDF investing additional funds into
such investee. MMR has received consent to increase its investment in Advent
Energy Limited (Advent) above 30%, which expires on 5 August 2017 (PDF
Consent).
As at 2 August 2016, MMR notified Innovation Australia that its total commitment
to Advent was $7,495,062 and that it had shareholders’ funds of $26,165,961. This
amounts to 28.64% of MMR’s committed capital.
The Offer Document produced by MMR provided that, assuming the maximum
subscription of $2,800,485 was raised, a total of $2,050,000 will be applied toward
funding the activities of Advent. The Offer Document did not disclose:
by MMR;
- any proposed fundraising to be undertaken by Advent other than funding
of the PDF Consent.
- the fact that MMR has been granted the PDF Consent;
- the fact that the PDF Consent expires in August 2017; or
- the conditions applicable to MMR that will need to be satisfied upon expiry
The capital restrictions of MMR are critical to investors and may have a material
impact on MMR’s ability to invest in Advent. In the absence of a further consent
from Innovation Australia, MMR will be required to reduce its investment before 5
August 2017 in order to ensure it remains in compliance with the PDF Act. A
company’s PDF status can be revoked in the event that the company is not in
compliance with the PDF Act. The Offer Document did not disclose the effect
that ceasing to be classed as a PDF would have on its shareholders, as this is a
material risk that shareholders should be aware of as the risk relates directly to
their personal taxation consequences.
In addition, the Offer Document (together with the Cleansing Notice and MMR’s
previous announcements) do not disclose details of the counterclaim or other
claims made by Grandbridge, Trandcorp and Mr Breeze against MMR and
Advent. Further, the Offer Document did not set out the dilutive effect on
shareholders that choose not to participate in the MMR Rights issue. The Offer
Document should include a statement setting out the extent to which
shareholders will be diluted in the event that they do not take up their
entitlements and those shares are subsequently placed to third parties by the
Directors.
- Forums
- ASX - By Stock
- MMR
- RE MMR S 249 Notice
RE MMR S 249 Notice
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MMR (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.236M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
MMR (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online